Clinical Infectious Diseases Impact Factor

The current movement is up from 7.3 for metric year 2024 to 8.3 for metric year 2025. The 2021 spike (20.9) was driven almost entirely by COVID-related clinical ID papers, including clinical guidance and epidemiological analyses that were referenced across medicine. The current 8.3 reflects the post-pandemic clinical ID baseline.

For authors, 8.3 is the right number to use for current planning. It accurately reflects the journal's position in the post-pandemic infectious disease publishing landscape.

CID's 8.3 JIF places it in the strong upper tier of infectious disease journals, but below the Lancet Infectious Diseases (29.4) and NEJM (84.5) for the biggest clinical ID stories. The Scopus-side picture is also strong: CiteScore is 17.1 and SJR is 2.992. The journal's real strength is its concentrated IDSA readership: virtually every practicing infectious disease physician in North America reads or monitors CID. That community reach adds value beyond the citation metric.

At 77,846 total cites, CID has one of the largest citation footprints in infectious disease publishing. That reflects both volume and community engagement. Papers here reach the people who make treatment decisions.

For manuscripts targeting Clinical Infectious Diseases, three patterns account for most of the desk rejections we see.

Observational studies without meaningful clinical sample sizes or practice-changing findings. CID's readership is practicing infectious disease physicians, and its editorial bar reflects that: the finding has to matter in a clinic or a public health program. We see observational studies that are technically competent (appropriate controls, reasonable analysis) but describe a finding that is already known or only marginally updates existing understanding in a small cohort.

A retrospective study of 80 patients with a fungal infection confirming a known risk factor is not a CID paper. The journal wants evidence that changes how clinicians or programs approach an infectious disease problem.

Microbiology or basic science papers submitted to a clinical journal. CID is the IDSA's clinical flagship, not a microbiology journal. We see submissions where the primary contribution is microbiological, new resistance mechanism characterization, in vitro activity data, animal model infection results, without human clinical data or a clear clinical consequence. Those papers belong in Antimicrobial Agents and Chemotherapy, Infection and Immunity, or Journal of Bacteriology. The clinical relevance needs to be demonstrated, not implied.

An excellent characterization of a new beta-lactamase variant becomes a CID paper when paired with clinical outcomes data linking that variant to treatment failure in human patients.

COVID-era papers past their clinical utility window. A disproportionate share of desk rejections we see now are COVID-related submissions, long COVID epidemiology, vaccine effectiveness in specific subgroups, or treatment studies from 2021-2022, where the clinical question has largely been answered by larger studies or where the finding no longer changes clinical practice given current guidance. CID editors are explicit about deprioritizing COVID submissions that don't advance a genuinely open clinical question.

If the COVID angle is the frame for what is otherwise a general infectious disease or immunology paper, recasting the frame around the more durable question is worth considering before submission.

A Clinical Infectious Diseases submission readiness check can help assess whether the clinical framing and evidence design meet CID's editorial bar before you commit to submission.

For submission logistics, CID uses Oxford's Editorial Manager system at https://www.editorialmanager.com/cid/. OUP's current author guidelines list a $5,001 OA licensing charge, $125 per finished typeset page in page-composition charges, and $550 per printed color figure on non-OA papers that print in color.

CID editors want clinical infectious disease work that matters to practicing ID physicians. That includes:

• treatment studies with clear clinical relevance

• antimicrobial resistance and stewardship data that informs practice

• epidemiological findings with practical implications

• guideline-informing evidence from well-designed studies

• diagnostic studies that change how ID is practiced

What gets filtered: primarily mechanistic or basic science work without clinical consequence, small case series without broader implications, and papers where the clinical ID angle is secondary.

It does not tell you whether the IDSA community will engage with the paper, whether the clinical consequence is broad enough for CID's readership, or whether Lancet ID is actually the better strategic target. The JIF places the journal in the hierarchy. The submission decision should turn on clinical relevance, study design strength, and whether the IDSA readership is the right audience.

Submit if:

• the manuscript reports a clinical infectious disease finding with direct implications for how ID physicians manage patients or public health programs

• the study design is rigorous, prospective cohort, randomized design, or large retrospective with appropriate controls

• the audience is the IDSA community of practicing ID physicians and clinical researchers in North America

• antimicrobial resistance, stewardship data, or epidemiological findings that will inform treatment guidelines

Think twice if:

• Lancet Infectious Diseases is a realistic target and the finding has global significance beyond North America

• the work is primarily mechanistic or microbiological without clear clinical implication, that belongs in journals like Infection and Immunity or mBio

• the clinical sample is small and the conclusion is preliminary rather than definitive

• the Journal of Infectious Diseases JIF 4.5 is a more appropriate scope fit for translational or basic-leaning ID work